L
Lorenz Trümper
Researcher at University of Göttingen
Publications - 276
Citations - 22696
Lorenz Trümper is an academic researcher from University of Göttingen. The author has contributed to research in topics: Lymphoma & Diffuse large B-cell lymphoma. The author has an hindex of 53, co-authored 260 publications receiving 19534 citations. Previous affiliations of Lorenz Trümper include Deutsche Forschungsgemeinschaft & University of Cologne.
Papers
More filters
Journal ArticleDOI
Dental and Periodontal Treatment Need after Dental Clearance Is Not Associated with the Outcome of Induction Therapy in Patients with Acute Leukemia: Results of a Retrospective Pilot Study
Gerhard Schmalz,Lulzim Tulani,Rilana Busjan,Rainer Haak,Tanja Kottmann,Lorenz Trümper,Justin Hasenkamp,Dirk Ziebolz +7 more
TL;DR: It can be concluded that remaining dental and periodontal treatment need as well asperiodontal inflammation after dental clearance is not associated with the outcome of induction therapy in adult patients with acute leukemia.
Posted ContentDOI
MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphoma
Jennifer Hüllein,Mikolaj Slabicki,Maciej Rosolowski,Alexander Jethwa,Stefan Habringer,Katarzyna Tomska,Roman Vladimirovich Kurilov,Junyan Lu,Sebastian Scheinost,Rabea Wagener,Zhiqin Huang,Marina Lukas,Yavorska O,Helferich H,René Scholtysik,Bonneau K,Donato Tedesco,Ralf Küppers,Wolfram Klapper,Christiane Pott,Stephan Stilgenbauer,Birgit Burkhardt,Markus W. Löffler,Lorenz Trümper,Michael Hummel,Benedikt Brors,Marc Zapatka,Reiner Siebert,Ulrich Keller,Wolfgang Huber,Markus Kreuz,Thorsten Zenz +31 more
TL;DR: The findings show that in TP53wt BL, MDM4-mediated inhibition of p53 is a mechanism to evade cell cycle arrest, and identifiesMDM4 as a key functional target of 1q gain in a wide range of cancers, which is therapeutically targetable.
Journal ArticleDOI
984TiPPHASE 3 TRIAL OF BRENTUXIMAB VEDOTIN AND CHP VERSUS CHOP IN THE FRONTLINE TREATMENT OF PATIENTS (PTS) WITH CD30+ MATURE T-CELL LYMPHOMAS (MTCL)
Timothy M Illidge,Barbara Pro,Lorenz Trümper,Emily K. Larsen,Dirk Huebner,Dana A. Kennedy,Owen A. O'Connor +6 more
TL;DR: This global trial is evaluating the safety and efficacy of 1.8 mg/kg brentuximab vedotin with CHP (A + CHP) vs CHOP for frontline treatment of CD30+ MTCL to compare progression-free survival between the 2 treatment arms as determined by an independent review facility (IRF).
Journal ArticleDOI
[Current and future indications for bendamustine: chronic lymphocytic leukemia, indolent lymphoma, mantle cell lymphoma and diffuse large B-cell lymphomas].
TL;DR: Dieser Fragestellung geht unter anderem die CLL12-Studie nach, bei der Patienten mit Binet-Stadium A, die nach biologischen and genetischen Parametern ein hohes oder sehr hohes Rezidivrisiko haben, behandelt werden.